After the impressive tumor-shrinking data shown by Amgen (AMGN) from its KRAS-targeted cancer drug at the recently completed ASCO meeting, attention — and pressure — now shift to Mirati Therapeutics (MRTX) and its competing KRAS blocker.

Mirati is administering its drug called MRTX849 to patients with solid tumors right now. The first data reveal from the early-stage clinical trial is coming later this year. Mirati isn’t being more precise on timing, but investor expectations are running high, which means this trial readout is now shaping up to be one of the most important stock-moving catalysts remaining on the 2019 biotech calendar.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy